Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +3.70%26 EV-to-FCF is 70.55 as of Sep. 05, 2026, which is 25% below its 10-year median of 93.84. GuruFocus rates ROCO:7762 with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 565 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 82.3% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pet Pharm Biotech Co's Enterprise Value is NT$3,119.7 Mil.
Pet Pharm Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$44.2 Mil. Therefore, Pet Pharm Biotech Co's EV-to-FCF for today is 70.55.
The historical rank and industry rank for Pet Pharm Biotech Co's EV-to-FCF or its related term are showing as below:
ROCO:7762'
s EV-to-FCF Range Over the Past 10 Years
Min: -20.44 Med: 93.84 Max: 765.38
Current: 70.55
During the past 4 years, the highest EV-to-FCF of Pet Pharm Biotech Co was 765.38. The lowest was -20.44. And the median was 93.84.
ROCO:7762's EV-to-FCF is ranked worse than 82.3% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.2
vs ROCO:7762: 70.55
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pet Pharm Biotech Co (ROCO:7762) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pet Pharm Biotech Co's PE Ratio (TTM) for today is calculated as:
Pet Pharm Biotech Co's share price for today is NT$58.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pet Pharm Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.516.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pet Pharm Biotech Co EV-to-FCF Related Terms
Pet Pharm Biotech Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's EV-to-FCF falls into.
Pet Pharm Biotech Co's current Enterprise Value is NT$3,119.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pet Pharm Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$44.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co (ROCO:7762) has a EV-to-FCF of 70.55 as of Sep. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pet Pharm Biotech Co and its competitors. This is 25% below median its historical median of 93.84. According to the industry distribution chart, Pet Pharm Biotech Co ranks #465 out of 565 companies in the Drug Manufacturers industry, placing it in the top 82.3%.
Is Pet Pharm Biotech Co's EV-to-FCF too high?
Pet Pharm Biotech Co's current EV-to-FCF of 70.55 is 25% below median its 10-year median of 93.84. The Drug Manufacturers industry median EV-to-FCF is 20.20. Pet Pharm Biotech Co's value of 70.55 is 249.3% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #465 out of 565 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pet Pharm Biotech Co has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #465 out of 565 companies for EV-to-FCF. This places Pet Pharm Biotech Co in the lower half of its industry. The industry median EV-to-FCF is 20.20. Pet Pharm Biotech Co's value of 70.55 is 249.3% above this benchmark. While the company's 10-year median is 93.84 vs. the industry median of 20.20, Pet Pharm Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.20, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current EV-to-FCF of 70.55 is 249.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current EV-to-FCF is 70.55, which is 25% below median its own 10-year median of 93.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current EV-to-FCF of 70.55. The current EV-to-FCF is 70.55, which is 25% below median its 10-year median of 93.84 and 249.3% above the Drug Manufacturers industry median of 20.20. Pet Pharm Biotech Co's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current EV-to-FCF is 70.55 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
26GF Score
Get the complete analysis for ROCO:7762
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
